Regeneron Pharmaceuticals' Q2 Earnings Exceed Estimates, Driven By Its Top-Selling Eczema And Eye Drugs
Portfolio Pulse from Vandana Singh
Regeneron Pharmaceuticals (NASDAQ: REGN) reported strong Q2 earnings, with adjusted EPS of $11.56 and sales of $3.55 billion, both exceeding estimates. Key drivers were Eylea HD, Dupixent, and Libtayo. Dupixent sales, recorded by Sanofi (NASDAQ: SNY), significantly contributed to Regeneron's revenue.
August 01, 2024 | 5:23 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Regeneron Pharmaceuticals reported strong Q2 earnings, with adjusted EPS of $11.56 and sales of $3.55 billion, both exceeding estimates. Key drivers were Eylea HD, Dupixent, and Libtayo.
The strong earnings report, driven by key products, indicates positive short-term momentum for Regeneron's stock price.
CONFIDENCE 100
IMPORTANCE 90
RELEVANCE 100
POSITIVE IMPACT
Sanofi's collaboration with Regeneron on Dupixent significantly contributed to Regeneron's Q2 revenue, with Dupixent sales recorded at $3.56 billion.
Sanofi's collaboration on Dupixent, which significantly contributed to Regeneron's revenue, suggests positive short-term impact for Sanofi.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 50